UCSF Benioff Children's Hospital Antimicrobial Susceptibility Gram-negatives Inpatient/ED

N/A-testing NOT APPLICABLE to organism. CZOL-cefazolin, CTRX-ceftriaxone, CTAZ-ceftazidime, CFPM-cefepime, GEN-gentamicin, TOB-tobramycin, T/S-trimethoprim/sulfamethoxazole, CIP-ciprofloxacin, IMI-imipenem-cilastatin, MER-meropenem, P/T-piperacillin-tazobactam

Values are % of strains testing susceptible to listed antibiotic. Unless indicated, results are for all inpatient/ED locations and culture sites.

Susceptibilities are based on data from 2020-2022. Isolate numbers and 95% confidence intervals are provided to gauge precision of susceptibility estimate. 

Organism Total Isolates*

CTRX

%S

(95% CI)

CTAZ

%S

(95% CI)

CFPM

%S

(95% CI)

GEN

%S

(95% CI)

TOB

%S

(95% CI)

T/S

%S

(95% CI)

CIP

%S

(95% CI)

P/T

%S

(95% CI)

MER/IMI**

%S

(95% CI)

Enterobacter cloacae

61

N/A

N/A

89 (98)#

(78,94)

100

(94,100)

98

(91,100)

98

(91,100)

95

(87,98)

72

(60,82)

98

(91,100)

Escherichia coli

290

87

(83,91)

94

(91,96)

93 (96)#

(90,95)

91

(88,94)

92

(88,95)

65

(60,71)

77

(73,82)

96

(93,98)

100

(99,100)

Klebsiella oxytoca

68

86

(77,93)

97

(90,99)

96 (95)#

(88,98)

97

(90,99)

95

(89,98)

89

(80,95)

94

(86,98)

83

(73,90)

100

(95,100)

Klebsiella pneumoniae

88

88

(80,94)

88

(80,94)

92 (95)#

(84,96)

88

(86,97)

95

(89,98)

77

(67,85)

81

(72,88)

98

(94,100)

100

(96,100)

Pseudomonas aeruginosa 109* N/A

88

(81,93)

92

(86,96)

N/A

94

(89,97)

N/A

86

(79,91)

83

(75,91)

91

(84,95)

Serratia marcescens

43

95

(85,99)

100

(92,100)

97 (100)#

(88,100)

95

(85,99)

93

(81,98)

97

(88,100)

95

(85,99)

97

(88,100)

100

(92,100)

*Pseudomonas aeruginosa isolates do not include isolates from patients with cystic fibrosis.

**Due to a change in susceptibility testing method, urine isolates from 2022 onward are tested for ertapenem and imipenem-cilastatin but not meropenem. Reported combined susceptibility to meropenem or imipenem-cilastatin is based on meropenem for non-urine isolates and imipenem-cilastatin for urine isolates. This should be considered an approximate estimate of population susceptibility because susceptibility of each of these antibiotics cannot be completely inferred from the other. 

# Number in parentheses represents the percentage of isolates both fully susceptible and susceptible-dose dependent to cefepime, for each organism. Susceptible-dose dependent isolates of Enterobacteriaceae are those with MIC 4 to 8 micrograms/mL for a cefepime dose of 50 mg/kg/dose iv q8h with maximum 2g/dose, as routinely recommended per BCH Pediatric Antimicrobial Dosing Guidelines, is anticipated to be active.